Literature DB >> 8073186

A blocking ELISA using a monoclonal antibody for the serological detection of Mycoplasma hyopneumoniae.

M F Le Potier1, P Abiven, M Kobisch, D Crevat, P Desmettre.   

Abstract

A blocking ELISA was developed by using a monoclonal antibody (4082-05-344-18) which specifically detected an epitope on the Mycoplasma hyopneumoniae 40 kDa membrane protein without cross-reacting with M flocculare or M hyorhinis. The results obtained with sera from specific pathogen-free pigs inoculated with M flocculare or M hyorhinis confirmed the specificity of the assay. An immunoblotting procedure was used to characterise the antibody response of pigs experimentally infected with M hyopneumoniae. Antibodies to the 40 kDa antigen were detected two weeks after infection and remained as major markers for at least 20 weeks. Cross-reacting antibodies to this antigen were not detected in convalescent sera from piglets infected with M flocculare or M hyorhinis. Sera from experimentally infected pigs were compared by means of the blocking ELISA and an indirect ELISA. The kinetics of ELISA antibodies after experimental inoculation were also studied. The detection of antibody was rather more stable for a longer time with the blocking ELISA than with the indirect ELISA. In an evaluation of more than 1000 sera from the field there was excellent agreement between the two methods.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8073186     DOI: 10.1016/0034-5288(94)90151-1

Source DB:  PubMed          Journal:  Res Vet Sci        ISSN: 0034-5288            Impact factor:   2.534


  2 in total

1.  The prevalence of Mycoplasma hyopneumoniae in pig herds in western Finland based on the demonstration of antibodies in colostrum by ELISA.

Authors:  E Rautiainen
Journal:  Acta Vet Scand       Date:  1998       Impact factor: 1.695

2.  Development of a blocking ELISA for detection of serum neutralizing antibodies against newly emerged duck Tembusu virus.

Authors:  Xuesong Li; Guoxin Li; Qiaoyang Teng; Lei Yu; Xiaogang Wu; Zejun Li
Journal:  PLoS One       Date:  2012-12-31       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.